Can testosterone injections be safely administered to a patient with severe chronic kidney disease (stage 5 chronic kidney disease)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Testosterone Injections in Severe CKD: Yes, They Can Be Safely Administered

Testosterone injections can be safely administered to patients with severe chronic kidney disease (stage 5 CKD), including those on dialysis, with appropriate monitoring and dose selection. The evidence supports their use for documented hypogonadism, with potential benefits for anemia, muscle mass, bone health, and quality of life, while recent data suggest no increased cardiovascular or mortality risk 1, 2.

Key Clinical Approach

Indications and Patient Selection

Testosterone replacement is indicated for hypogonadal men with CKD stage 5 when documented by:

  • Total testosterone <200-300 ng/dL on two separate morning measurements
  • Clinical symptoms (fatigue, decreased libido, muscle wasting, anemia)
  • No absolute contraindications (active prostate or breast cancer) 3

The prevalence of hypogonadism in severe CKD is extremely high (30-70%), making screening clinically relevant 2, 4. The underlying mechanism is testicular failure (both Leydig and Sertoli cell dysfunction), not hypothalamic-pituitary dysfunction 5.

Formulation Selection: Critical for CKD Patients

For severe CKD patients, transdermal testosterone gel is preferable to intramuscular injections 2. Here's why:

  • Intramuscular testosterone (enanthate or cypionate): 50-400 mg every 2-4 weeks creates supraphysiological peaks 2-5 days post-injection, followed by subtherapeutic troughs by days 10-14 3, 6. This roller-coaster pattern increases risk of excessive erythrocytosis—a particular concern in CKD patients who already have altered erythropoiesis 2.

  • Transdermal gel: Provides stable physiological testosterone levels without peaks, reducing erythrocytosis risk while maintaining efficacy 2.

However, if cost is prohibitive (annual cost ~$2,135 for transdermal vs. ~$156 for intramuscular 7), intramuscular injections remain acceptable with closer hematocrit monitoring.

Dosing Considerations

Standard replacement doses apply without adjustment for renal function 6, 8:

  • Intramuscular: 50-150 mg every 7-14 days (more frequent, lower doses preferred over 200-300 mg every 2-3 weeks) 3
  • Transdermal gel: Standard daily dosing per product labeling
  • Target mid-to-upper normal testosterone range (not supraphysiological levels) 9

No dose reduction is required for CKD stage 5 because testosterone metabolism occurs primarily in the liver, not the kidney 6, 8.

Monitoring Protocol: More Intensive Than General Population

Baseline Assessment (Mandatory)

  • Digital rectal exam and PSA level
  • Hematocrit/hemoglobin
  • Voiding symptoms assessment
  • Sleep apnea history 3, 9

Follow-up Schedule

  • First visit: 1-2 months to assess efficacy and adjust dose 9
  • Ongoing: Every 3-6 months during first year, then every 6-12 months 3, 9

At Each Visit Monitor:

  • Hematocrit (most critical in CKD): If >52%, temporarily withhold therapy, reduce dose, or perform phlebotomy 3. CKD patients are particularly susceptible to erythrocytosis.
  • PSA levels: Refer to urology if PSA >4.0 ng/mL, abnormal digital rectal exam, or PSA velocity >0.75 ng/mL/year (even if <4.0) 9
  • Testosterone levels: Measure just before next injection (for IM) or anytime (for transdermal). Adjust if suboptimal response with low-normal levels 9
  • Renal function: While testosterone doesn't directly harm kidneys, monitor eGFR as emerging data suggest potential renoprotective effects 2

Expected Benefits in CKD Population

Based on trials specific to CKD patients:

  • Anemia improvement: Hemoglobin increase of ~1.4 g/dL (from 6.8 to 8.2 g/dL in dialysis patients) 10
  • Muscle mass and strength: Clinically meaningful improvements 8, 11, 2
  • Bone mineral density: Improvements observed 8, 11
  • Quality of life and sexual function: Moderate improvements 8, 2
  • Mortality: Recent propensity-matched data show 22% lower all-cause mortality (HR 0.78) 1

Safety Profile: Reassuring Recent Data

The most robust recent evidence (2026 propensity-matched cohort, n=3,090) found no increased risk of:

  • Cardiovascular events (MI, stroke, heart failure)
  • Prostate cancer
  • Dementia
  • And showed improved survival 1

Relative Contraindications in CKD

  • Erythrocytosis (hematocrit >52%)
  • Severe sleep apnea (uncontrolled)
  • Significant peripheral edema
  • Benign prostatic hyperplasia with severe voiding symptoms 3

These are relative contraindications—optimize the underlying condition first, then reconsider testosterone.

Common Pitfalls to Avoid

  1. Using high-dose, infrequent IM injections: The traditional 200-300 mg every 2-3 weeks creates problematic peaks and troughs. Use 50-150 mg every 7-14 days instead 3.

  2. Failing to monitor hematocrit closely: CKD patients have altered erythropoiesis; excessive erythrocytosis is the most common serious adverse effect 3, 10.

  3. Initiating therapy without baseline PSA/DRE: Prostate cancer must be excluded first 3, 9.

  4. Expecting immediate anemia correction: While testosterone stimulates erythropoiesis, it doesn't replace erythropoietin-stimulating agents in modern CKD management 11.

  5. Discontinuing therapy prematurely: Benefits for muscle mass, bone density, and quality of life require sustained treatment (3-6 months minimum) 8, 11.

Special Consideration: Dialysis vs. Pre-Dialysis

Testosterone can be used in both non-dialysis CKD stage 5 and dialysis patients 10, 12, 8. Historical data from the 1970s-1980s focused on dialysis patients and showed clear hematologic benefits 10, 12. Modern evidence extends safety and efficacy across all CKD stage 5 patients 1, 2.

Bottom Line Algorithm

  1. Screen symptomatic male CKD stage 5 patients with morning total testosterone (two measurements)
  2. If testosterone <200-300 ng/dL with symptoms: Proceed with baseline assessment (PSA, DRE, hematocrit, voiding symptoms)
  3. If no contraindications: Initiate testosterone (prefer transdermal gel; if cost-prohibitive, use low-dose frequent IM injections)
  4. Monitor hematocrit and PSA more closely than general population (every 3-6 months initially)
  5. Adjust dose based on symptom response and testosterone levels (target mid-to-upper normal range)
  6. Continue long-term if beneficial and well-tolerated; benefits are sustained, not temporary 8, 2

References

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.